Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 14/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trandolaprilat SCHEMBL156829 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL11076552 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL5567196 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173132 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL683838 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173121 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL11286342 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL5794079 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173113 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL7388097 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4425355-A | HYPOTENSIVE | WARNER-LAMBERT COMPANY (US) | 1984-01-10 | — | — | US | claimed |
| EP-0088342-A1 | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1983-09-14 | — | — | EP | claimed |
| EP-0037231-A2 | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1981-10-07 | — | — | EP | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7678782-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-2021000-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | Braincells, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20050186261-A1 | Compositions and methods for treating contracture | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-4584299-A | MIXTURE OF HYPOTENSIVE AND CARDIOTONIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1986-04-22 | — | — | US | disclosed |
| US-4490386-A | Phosphate salts of 1-[2-[(1-alkoxycarbonyl-3-aralkyl)-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof | WARNER-LAMBERT COMPANY (US) | 1984-12-25 | — | — | US | disclosed |
| US-4425355-A | HYPOTENSIVE | WARNER-LAMBERT COMPANY (US) | 1984-01-10 | — | — | US | disclosed |
| EP-0088342-A1 | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
| US-4350704-A | HYPOTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1982-09-21 | — | — | US | disclosed |
| EP-0037231-A2 | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1981-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | ACE 1695/4885MEN1 4231/4885KMT2A 4861/4885 |
| US-20050186261-A1 | Compositions and methods for treating contracture | COL2A1, FN1, TNNC1 | ACE 2860/4885MEN1 1534/4885KMT2A 3332/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885MEN1 3647/4885KMT2A 2044/4885 |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885MEN1 2541/4885KMT2A 2068/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885MEN1 1910/4885KMT2A 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.